FORTUNE -- The first time I ever spoke with venture capitalist Jeff Fagnan was January 2009. I had heard that his firm, Atlas Venture, was cutting back on staff after finishing up fundraising more than $100 million below its $400 million target (and an even farther cry from the $750 million it had raised in the dotcom heyday). Not too enjoyable of a conversation. Neither was a follow-up about how Atlas basically would begin to wind down its London office, which meant additional layoffs.
At the time, Fagnan sounded hopeful that Atlas could turn things around by slimming down and refocusing. I was highly skeptical because, well, few VC firms survive a steep fall from grace. Remember, Atlas once had more than a dozen partners and offices all over Europe and North America. Now it was just a small handful of folks in Boston – with a lot less cash and very questionable future prospects.
But it seems I was wrong. The firm has just closed on its ninth fund with $265 million in capital commitments, which is $15 million above what it had been calling its hard cap. And there was plenty of over-subscription beyond that.
So Fagnan seemed to be in much better spirits yesterday when we had lunch to discuss the news. He explained that the big change was refocusing almost all of the firm's new deal activity around Boston (save for a few opportunistic Valley plays), with a focus on providing lots of seed capital (<$1m) before agreeing to lead Series A's.
"You can actually get lots of data now with relatively little money," Fagnan explains, adding that he views 'signaling risk' concerns as overblown. "Seeds also let us get checks to the entrepreneurs faster, and the entrepreneur knows we have pockets deep enough to do the Series A if things are progressing in the right direction."
He adds that this strategy is working not only for IT, but also for life sciences (where Atlas investments mostly in biotherapeutics – often partnering early with big pharma on development/option deals).
"I think they're going to dominate the Boston seed market, maybe alongside Google Ventures, because they spend their time in Boston instead of in New York" says an Atlas limited partner. "I cannot think of another firm that's gone through such a transformation and came out on the other side."
Sign up for Dan's daily email newsletter on deals and deal-makers: GetTermSheet.com
Tips for navigating early-stage investments in biotech.
By Bruce Booth, contributor
Venture capital is often called an apprenticeship business because experience matters and takes time to accumulate. But successful firms are able to translate and transfer experiential wisdom through institutional memory, which involves codifying what works and what doesn't. Back in 2007, we did this with our life science team by pulling together a detailed list of "Lessons Learned" from our existing MOREFeb 12, 2013 12:55 PM ET
A significant development for Boston's venture capital market.
Boston-area venture capitalist Ryan Moore has agreed to join Atlas Venture as a partner, Fortune has learned. He had spent the past 12 years with GrandBanks Capital, where his deals have included Enpocket (sold to Nokia), GlassHouse Technologies (in registration for an IPO) and Vivox.
This is a significant move for a number of reasons. So I'm going to list them in no particular MOREDan Primack - Sep 13, 2011 9:21 AM ET
New research on the VC industry turns conventional wisdom on its head.
In the world of venture capital, tech is the movie star and life sciences the second banana. The champion and the also-ran. Just look at the most recent Forbes Midas List, in which the first life sciences investor doesn't appear until #16 (Bryan Roberts of Venrock).
But new research suggests that this hierarchy has quietly reversed itself over the past MOREDan Primack - Jul 11, 2011 9:19 AM ET
|China's fastest-growing cities for millionaires|
|Google files First Amendment court case against NSA surveillance secrecy|
|Chrysler relents, agrees to recall 2.7 million Jeeps|
|Immigration bill could cut deficits by $175 billion - CBO|
|Why Apple's new MacBook Air is the ultimate road warrior's notebook|